MUSTANG BIO INC
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 3. Legal Proceedings
We have submitted a joint voluntary notice to the U.S. Committee on Foreign Investment in the United States (“CFIUS”) in connection with the sale of manufacturing facility and associated assets to a third party. Such transaction is currently under review by CFIUS. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Recent Developments” for additional information.
Except as set forth above, we are not involved in any legal proceedings that we believe could have a material adverse effect on our financial position or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers, threatened against or affecting our company or our officers or directors in their capacities as such.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.